Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

Hdl Handle:
http://hdl.handle.net/10675.2/801
Title:
Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
Authors:
Zhou, Gang; Levitsky, Hyam
Abstract:
The past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) ipilimumab for advanced melanoma. In addition, the clinical evaluations of a variety of promising immunotherapy drugs are well under way. Benefiting from more efficacious immunotherapeutic agents and treatment strategies, a number of recent clinical studies have achieved unprecedented therapeutic outcomes in some patients with certain types of cancers. Despite these advances, however, the efficacy of most cancer immunotherapies currently under clinical development has been modest. A recurring scenario is that therapeutic maneuvers initially led to measurable antitumor immune responses in cancer patients but ultimately failed to improve patient outcomes. It is increasingly recognized that tumor cells can antagonize therapy-induced immune attacks through a variety of counterregulation mechanisms, which represent a fundamental barrier to the success of cancer immunotherapy. Herein we summarize the findings from some recent preclinical and clinical studies, focusing on how tumor cells advance their survival and expansion by hijacking therapy-induced immune effector mechanisms that would otherwise mediate their destruction.
Citation:
Clin Dev Immunol. 2012 May 31; 2012:124187
Issue Date:
31-May-2012
URI:
http://hdl.handle.net/10675.2/801
DOI:
10.1155/2012/124187
PubMed ID:
22778760
PubMed Central ID:
PMC3386616
Type:
Article
ISSN:
1740-2530
Appears in Collections:
Georgia Cancer Center: Faculty Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorZhou, Gangen_US
dc.contributor.authorLevitsky, Hyamen_US
dc.date.accessioned2012-10-26T20:30:46Z-
dc.date.available2012-10-26T20:30:46Z-
dc.date.issued2012-05-31en_US
dc.identifier.citationClin Dev Immunol. 2012 May 31; 2012:124187en_US
dc.identifier.issn1740-2530en_US
dc.identifier.pmid22778760en_US
dc.identifier.doi10.1155/2012/124187en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/801-
dc.description.abstractThe past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) ipilimumab for advanced melanoma. In addition, the clinical evaluations of a variety of promising immunotherapy drugs are well under way. Benefiting from more efficacious immunotherapeutic agents and treatment strategies, a number of recent clinical studies have achieved unprecedented therapeutic outcomes in some patients with certain types of cancers. Despite these advances, however, the efficacy of most cancer immunotherapies currently under clinical development has been modest. A recurring scenario is that therapeutic maneuvers initially led to measurable antitumor immune responses in cancer patients but ultimately failed to improve patient outcomes. It is increasingly recognized that tumor cells can antagonize therapy-induced immune attacks through a variety of counterregulation mechanisms, which represent a fundamental barrier to the success of cancer immunotherapy. Herein we summarize the findings from some recent preclinical and clinical studies, focusing on how tumor cells advance their survival and expansion by hijacking therapy-induced immune effector mechanisms that would otherwise mediate their destruction.en_US
dc.rightsCopyright © 2012 G. Zhou and H. Levitsky.en_US
dc.subjectReview Articleen_US
dc.titleTowards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escapeen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3386616en_US
dc.contributor.corporatenameGHSU Cancer Center-
dc.contributor.corporatenameDepartment of Medicine-

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.